Abstract

The amount of gas in ultrasound contrast agents is related to their acoustic activity. Because of this relationship, gas volume has been used as a key variable in normalizing the in vitro and in vivo acoustic behavior of lipid shell-stabilized bubbles with different sizes and shell components. Despite its importance, bubble gas volume has typically only been theoretically calculated based on bubble size and concentration that is typically measured using the Coulter counter for microbubbles and nanoparticle tracking analysis (NTA) for nanoscale bubbles. However, while these methods have been validated for the analysis of liquid or solid particles, their application in bubble analysis has not been rigorously studied. We have previously shown that resonant mass measurement (RMM) may be a better-suited technique for sub-micron bubble analysis, as it can measure both buoyant and non-buoyant particle size and concentration. Here, we provide validation of RMM bubble analysis by using headspace gas chromatography/mass spectrometry (GC/MS) to experimentally measure the gas volume of the bubble samples. This measurement was then used as ground truth to test the accuracy of theoretical gas volume predictions based on RMM, NTA (for nanobubbles), and Coulter counter (for microbubbles) measurements. The results show that the headspace GC/MS gas volume measurements agreed well with the theoretical predictions for the RMM of nanobubbles but not NTA. For nanobubbles, the theoretical gas volume using RMM was 10% lower than the experimental GC/MS measurements; meanwhile, using NTA resulted in an 82% lower predicted gas volume. For microbubbles, the experimental gas volume from the GC/MS measurements was 27% lower compared to RMM and 72% less compared to the Coulter counter results. This study demonstrates that the gas volume of nanobubbles and microbubbles can be reliably measured using headspace GC/MS to validate bubble size measurement techniques. We also conclude that the accuracy of theoretical predictions is highly dependent on proper size and concentration measurements.

Highlights

  • Ultrasound (US) is a noninvasive, safe, accessible, and inexpensive medical imaging modality widely used around the world

  • We quantified the amount of perfluoropropane (C3F8) gas released by lipid-shelled nanobubbles and microbubbles, using headspace gas chromatography/mass spectrometry (GC/MS), following a previously published report [25,38]

  • The microbubbles had a higher ultrasound signal enhancement compared to nanobubbles

Read more

Summary

Introduction

Ultrasound (US) is a noninvasive, safe, accessible, and inexpensive medical imaging modality widely used around the world. There are currently three commercially available microbubble contrast agents approved by the Food and Drug Administration (FDA) for clinical use: Optison (GE Healthcare) and Definity (Lantheus), which are protein- or phospholipid-shell stabilized microbubbles of perfluoropropane (C3F8) gas, and Lumason/Sonovue (Bracco), which are lipid-shell stabilized sulfur hexafluoride (SF6) bubbles [2]. While microbubbles are a robust intravascular blood pool contrast agent [3,4], they have shown short circulation times (on the order of 2–10 min) arising from the dissolution of the gas into the surrounding medium. Stable sub-micron or nanobubbles extend bubble circulation time and have been shown to localize beyond the tumor vasculature via the enhanced permeability effect (EPR) [8,9], offering many new potential ultrasound contrast agent (UCA) applications for tumor imaging and therapy

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call